Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

n Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy of SNS-595, SNS-032 and SNS-314, planned additional clinical testing and development efforts, the timing of enrollment in clinical trials and the announcement of clinical results. Words such as "look forward," "suggests," "may," "expects," "designed," "believe," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities, including enrollment and reporting of results, could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for SNS-595, SNS-032 and/or SNS-314 may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials and manufacturing of SNS-595, SNS-032 and SNS-314 and risks related to Sunesis' need for additional funding. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' annual report on Form 10-K for the year ended December 31, 2006 and other filings with the Securities and Exchange Commission.
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... The Movement for Indefinite Life Extension (MILE) ... technologies and awareness. The event is taking place from ... 21st 2015, in a live Google Hangout broadcast from ... of MILE, says, “Our lives are in our hands, ... Indefinite Life Extension is raising awareness about bio-sciences and ...
(Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
(Date:2/26/2015)... Feb. 26, 2015 BioEnterprise today announced that ... attracted more than $2 billion in growth funding during ... national investors, strategic sources, state – including the Ohio ... the $2 billion has been raised in the past ... the heels of the BioEnterprise Midwest Healthcare Growth ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2
... Jan. 19, 2011 LifeVantage Corporation (OTC Bulletin ... to oxidative stress, announced preliminary unaudited net revenue for its ... of approximately $7.4 million for the three month period ended ... million or 15% over net revenue of $6.4 million for ...
... University have placed nanocrystals of rock salt into lead ... heat-generating items such as vehicle exhaust systems, industrial processes ... have seen in the past. The material exhibits ... to enable 14 percent of heat waste to electricity, ...
... Masimo (Nasdaq: MASI ... clinical accuracy of its noninvasive and continuous hemoglobin (SpHb®) monitoring ... for Technology in Anesthesia (STA) Annual Meeting . ... evaluated the accuracy of Masimo SpHb— a noninvasive measurement ...
Cached Biology Technology:LifeVantage Announces Preliminary Unaudited Second Quarter 2011 Results 2LifeVantage Announces Preliminary Unaudited Second Quarter 2011 Results 3Breakthrough in converting heat waste to electricity 2New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 2New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 3New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 4New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 5New Johns Hopkins School of Medicine Study Shows Masimo Noninvasive Hemoglobin Monitoring is Accurate During Complex Spine Surgeries 6
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... the United States are 32 times more likely to ... antibiotic, gentamicin, than others outside the poultry industry, according ... Johns Hopkins Bloomberg School of Public Health. While drug-resistant ... industrial broiler chicken environment, this is the first U.S. ...
... possum and a giant rat were recorded by scientists as ... and virtually unknown Lost World in the pristine wilderness of ... Indonesia Institute of Science (LIPI) scientists were accompanied by the ... its wildlife on an expedition to the Fojas in June ...
... the Neural Basis of Cognition (CNBC), a joint project ... have for the first time described a mechanism called ... the fly allowing stimuli to be more keenly sensed. ... the January 2008 issue of Nature Neuroscience, and available ...
Cached Biology News:Poultry workers at increased risk of carrying antibiotic-resistant E. coli 2Indonesia's 'Lost World' reveals more surprises 2Neuronal circuits able to rewire on the fly to sharpen senses 2
Request Info...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
... Anti-PLCδ-1, clone d1-174 GenBank Accession ... and X-press N-terminal tagged fusion protein corresponding ... Formulation: 0.1M Tris-glycine, pH 7.4, 0.15M NaCl, ... glycerol to 30% Quality Assurance: routinely evaluated ...
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Biology Products: